ArticleFrontiers in artificial intelligence2026
Hybrid neutrosophic enhanced MobileNetV2 model for leukemia blood cell classification.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Leukemia is a type of cancer that originates in the bone marrow, causing uncontrolled production of abnormal white blood cells that disrupt normal blood function and weaken the immune system. Manual inspection is time-consuming and error-prone, relying heavily on the expertise and experience of medical professionals. Methods: The proposed study presents a hybrid model for classifying leukemia by integrating transfer learning and neutrosophic domain enhancement. Neutrosophic domain transformation splits the RGB channel image into Truth (T), Falsity (F), and Indeterminacy (I) components to address uncertainty, ambiguity, and poor contrast in blood cell representations. This enables the improvement of features more directly linked to leukemia identification. The images are augmented using wavelet sharpening and contrast-limited adaptive histogram equalization (CLAHE) on the T component, total variation minimization (TVM) on the F component, and wavelet shrinkage denoising on the I component. Results: This framework was trained and tested on the Leukemia Blood Cell Image Classification dataset, which included 3,256 peripheral blood smear (PBS) images across 4 classes: Benign, Early, Pre, and Pro. A transfer learning architecture based on MobileNetV2 was used for classification, and training was conducted using a 70:15:15 split for training, validation, and testing, respectively. The proposed neutrosophic-enhanced MobileNetV2 model achieved an overall testing accuracy of 98.36% and a macro F1-score of 0.98, demonstrating significant enhancement in multi-class leukemia classification. Discussions: The incorporation of the neutrosophic enhancement method significantly improves classifier performance, resulting in higher accuracy without increasing computational power.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.